Irena Melnikova
Direktor/Vorstandsmitglied bei Crossbow Therapeutics, Inc.
Profil
Irena Melnikova is Executive Director, WWBD and Partner at Pfizer Ventures.
Irena is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer.
She is an accomplished biopharma and finance executive with over 20 years of experience in equity financings in both public and private markets, corporate strategy, business development, and operations.
Most recently, Irena served as the Chief Financial Officer at Umoja Biopharma where she was a senior member of the executive team responsible for all aspects of financial strategy and operations of the company.
Prior to Umoja, Irena served as a Managing Director, Biopharma Investment Banking at SVB Leerink (now SVB Securities), where she provided critical advice to biopharma companies and their boards on equity financing strategies, completing over 80 transactions raising over $9 billion for clients.
Earlier in her career, Irena held leadership positions at Sanofi and TVM Capital; the latter - a global life sciences venture capital firm.
Irena brings strong scientific background and proven capacity to work across a wide range of therapeutic areas and technology platforms.
She earned a Ph.D.
in Molecular Medicine/Molecular Biology from the University of Texas.
Aktive Positionen von Irena Melnikova
| Unternehmen | Position | Beginn |
|---|---|---|
TVM Capital Corp.
 TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 19.06.2009 |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Private Equity Investor | 01.09.2022 |
Crossbow Therapeutics, Inc.
 Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Irena Melnikova
| Unternehmen | Position | Ende |
|---|---|---|
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Corporate Officer/Principal | 31.12.2007 |
TransForm Pharmaceuticals, Inc.
 TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Corporate Officer/Principal | - |
Ausbildung von Irena Melnikova
| The University of Texas at Austin | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
TVM Capital Corp.
TVM Capital Corp. Investment ManagersFinance TVM Capital Corp (TVM Capital) is a venture capital subsidary of TVM Capital GmbH founded in 1986. The firm is headquartered in Boston, Massachusetts. | Finance |
Leerink Partners LLC
Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |
TransForm Pharmaceuticals, Inc.
TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Health Technology |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Finance |
Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Crossbow Therapeutics, Inc. is a biotechnology company that aims to improve the lives of people with cancer by developing next-generation immunotherapies. The company is based in Cambridge, MA, and the CEO of the company is Briggs W. Morrison. The company's T-bolt™ therapies are designed to target previously unreachable cancer cell targets with high precision. Crossbow's approach is efficient and selective, allowing them to target the entire universe of cancer proteins, which expands the potential of antibody therapy to address many types of cancer. | Health Technology |
